SLC2A3 and neoplasm: In contrast, in tumors such as PRAD, CHOL, or TARGET-ALL, low SLC2A3 expression may be associated with tumor-specific metabolic dependencies or distinct immune microenvironment features, such as low glycolytic reliance, immune evasion mechanisms, or a more aggressive phenotype, resulting in poorer prognosis for patients with low expression (41).